The EVMS Office of Research has announced Round 3 funding opportunities for the Ryan Translational Research Fund grant.
The fund, a relatively new internal grant initiative, encourages creative and risk-taking research that promotes the multidirectional integration of basic science research, patient-oriented clinical research and population-based research with a long-term goal of improving public health.
Louis and Prudence Ryan, Norfolk community leaders and philanthropists, created the Ryan Translational Research Fund in 2019 with a generous gift to EVMS.
David Mu, PhD, Professor of Microbiology and Molecular Cell Biology, recently was awarded $90,000 through the initiative’s second round of funding.
Dr. Mu’s project is titled “Investigation of Lung Cancer Vulnerability to Common Cholesterol and Diabetes Medications.”
Through his research, Dr. Mu and his co-investigators on the grant, including Eric Feliberti, MD, Associate Professor of Surgery and Robert Campbell, PhD, Assistant Professor in the School of Health Professions, will investigate how TTF-1 expression status influence lung cancer vulnerability to metformin.
The teams also will analyze lung cancer risks in the patients who have received statins and/or metformin therapies. The study outcome is expected to facilitate the translation of applying these common and affordable medications in an oncology setting.
Find out more about The Ryan Translational Research Fund.
Read about the fund in EVMS magazine.